ClinicalTrials.gg
Active, not recruitingNCT03535298DELIVER-MSUpdated Aug 31, 2026

Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

A Phase 4 interventional study of Early Highly Effective Therapies Group and Escalation Therapies Group in Multiple Sclerosis, Relapsing-Remitting, sponsored by The Cleveland Clinic. Active, not recruiting at 30 sites in 2 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by The Cleveland Clinic · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
800
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies testing natalizumab in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, 1 under way, none of them phase 3. Natalizumab · Multiple Sclerosis, Relapsing-Remitting.

Planned enrollment
4th of 21
800 · median 110
Started
2019
the only one that year
Phase 4
8 of 21
none open now
Registered
18th of 21
by date
Lead sponsor
1 of 21
The Cleveland Clinic

Among the 21 studies testing natalizumab in Multiple Sclerosis, Relapsing-Remitting, this one is the 4th largest by planned enrollment, is the only one that started in 2019, is one of 8 in phase 4, and was the 18th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

None of the 21 studies testing natalizumab in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →

About natalizumab

Natalizumab: first FDA approval 2004 (TYSABRI), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies testing natalizumab in Multiple Sclerosis, Relapsing-Remitting as a file.
02

Study summary

The DELIVER-MS study seeks to answer the question: Does early treatment with highly effective DMT improve the prognosis for people with MS? This is an area of significant controversy and no data currently exist to guide treatment choices for patients and clinicians. The study results will help guide overall treatment philosophy and will be applicable not only to a wide range of existing therapies but also to new therapies, meeting a significant unmet need in patient decision making and aiding the decision for medication approval by third parties.

Read the detailed description

DELIVER-MS is a multi-center pragmatic comparative effectiveness randomized clinical trial with additional-parallel observational cohort. It aims to enroll up to 400 individuals newly diagnosed with RRMS and randomize them 1:1 to Early Highly Effective (EHT) or Escalation (ESC) treatment paradigms, based on the use of different disease modifying therapies (DMT) as first-line therapy. EHT approach to DMT is defined as use of one of five monoclonal antibodies (alemtuzumab, natalizumab, rituximab, ocrelizumab, ofatumumab, ublituximab) as first-line therapy. ESC approach is defined as initiating any other approved MS DMT as first-line therapy, then escalating to a more effective therapy upon disease activity. Once randomized, the Neurologist and Participant decide which DMT within the arm is most appropriate. After the initial DMT is initiated, if a DMT change is needed, the second-line therapy may be chosen from either arm, regardless of randomization. The randomization only applies to the initial DMT choice.

Up to 400 individuals who do are not amenable to randomization or who agree to randomization but are not approved for coverage for a medication in the arm to which they were randomized will enter the Observational Arm. In the Observational Arm, the DMT chosen is from any approved DMT for MS and is chosen by the Neurologist and participant.

All study procedures throughout are identical between the randomized and observation alarm, except for the randomization.

The primary objective for the initial 36 months of the study is normalized whole brain volume loss, measured using MRI from baseline to Month 36. The primary objective for the long term extension of the study (Months 48-108) is the EDSS+, a composite measure of clinical disability based on the EDSS and MSFC.

The study is performed primarily in tertiary MS Centers in the US and UK.

03

Conditions studied

  • Multiple Sclerosis, Relapsing-Remitting
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women aged 18 to 60 years.
  2. Established diagnosis of MS, as defined by the 2017 revision of McDonald Diagnostic Criteria (99).
  3. RRMS disease course as defined by the 2013 revisions of the MS clinical course definition (4).
  4. Participants must have evidence of active disease based on: one or more MS relapses within the last 18 months prior to screening visit or radiological evidence of MS activity (≥2 new T2 lesions within the last 12 months from screening [compared to a previous recent MRI within 18 months of screening] or ≥1 GdE demonstrated on brain or spinal cord MRI performed within the last 12 months of screening).
  5. Participants must be ambulatory with disease onset ≤ 5 years and treatment-naïve (i.e., no MS DMT at any time in the past).
  6. Participants must be eligible to receive at least one form of DMT within each treatment arm.
  7. EDSS at Baseline visit ≤ 6.5

Exclusion criteria

Exclusion Criteria:

  1. Participants with to all forms of DMT in either of the treatment arms.
  2. Participants must never have received any of the following medications: natalizumab, alemtuzumab, ocrelizumab, rituximab, ofatumumab, cladribine, siponimod, interferon beta-1a, interferon beta-1b, pegylated interferon beta-1a, glatiramer acetate, fingolimod, teriflunomide, dimethyl fumarate, daclizumab, mitoxantrone, diroximel fumarate, ozanimod, monomethyl fumarate, ponesimod.
  3. Participants must have not received any of the following medications, for reasons other than MS, in the last 12 months: cyclophosphamide, azathioprine, mycophenolate mofetil, cyclosporine, methotrexate, leflunomide, laquinimod, atacicept, other monoclonal antibodies.
  4. Participants with medical or surgical conditions that, in the opinion of the investigator, would put the subject at risk by participating in the study
  5. Participants unable to provide .
  6. Contraindication or inability to undergo MRI with Gd due to metal or metal implants, allergy to Gd contrast, claustrophobia, pain, spasticity, or excessive movement related to tremor.
  7. Unwillingness or inability to comply with the requirements of this protocol including the presence of any condition (physical, mental, or social) that, in the opinion of the PI, is likely to affect the participant's ability to comply with the study protocol.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
800 participants (estimated)

Study arms

  • Experimental
    EHT: Early Highly-effective

    Participants randomized to the "EHT: Early Highly-effective" arm will receive one of the highly effective MS therapies (Ocrevus, Lemtrada, Tysabri, Rituximab, Kesimpta) as their initial disease modifying treatment. Interventions: one of the highly effective MS therapies The randomization affects only the INITIAL treatment received. Once that treatment has been initiated, any subsequent changes are made according to standard clinical practice, regardless of randomization group.

    Drug: Early Highly Effective Therapies Group

  • Experimental
    ESC: Escalation

    Participants randomized to the "ESC: Escalation" arm will receive any other approved MS therapy (not one of the EHT group) as their initial disease modifying treatment. Interventions: one of the MS therapies NOT in the highly effective group The randomization affects only the INITIAL treatment received. Once that treatment has been initiated, any subsequent changes are made according to standard clinical practice, regardless of randomization group.

    Drug: Escalation Therapies Group

  • No intervention
    OBS: Observational

    Participants will not be restricted to a group of MS therapies. Participants enter this arm if they are not comfortable with randomization, are not eligible to receive any of the options in a randomized arm, or are not able to secure insurance coverage for any therapy in a randomized arm.

Interventions

  • DrugNatalizumabStudies of NatalizumabNatalizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Highly Effective MS Therapy group of medications

    Also known as: Lemtrada (alemtuzumab), Ocrevus (ocrelizumab), Tysabri (natalizumab), Rituxan (rituximab), Kesimpta (ofatumumab), Briumvi (ublituximab)

  • DrugGlatiramerStudies of GlatiramerGlatiramer pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Escalation MS Therapy group of medications

    Also known as: Betaseron (beta interferon), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Extavia (beta interferon), Gilenya (fingolimod), Glatopa (glatiramer acetate), Plegridy (beta interferon), Rebif (beta interferon), Tecfidera (dimethyl fumarate), Avonex (beta interferon), Mavenclad (cladribine), Mayzent (siponimod), Vumerity (diroximel fumarate), Zeposia (ozanimod), Bafiertam (monomethyl fumarate), Ponvory (ponesimod)

06

What researchers measure

Primary outcomes

  1. Brain volume loss, baseline to month 36

    To determine whether an EHT approach to DMT, defined as use of one of four monoclonal antibodies (alemtuzumab, natalizumab, rituximab, or ocrelizumab) as first-line therapy, is more effective than an escalation of treatment approach in reducing normalized whole brain volume loss measured using MRI in PwRRMS from Baseline to Month 36.

    Time frame: Baseline to 36 months

  2. EDSS+, month 48 to month 108

    To determine whether an EHT approach to DMT, defined as use of one of six monoclonal antibodies (alemtuzumab, natalizumab, rituximab, ocrelizumab, ofatumumab, ublituximab) as first-line therapy, is more effective than an escalation of treatment approach in reducing time to reach a multidimensional composite comprised of EDSS+ worsening. EDSS+ worsening will be defined as worsening on ⩾ 1 of the 3 components: EDSS, 9HPT, or T25FW, which is confirmed at another visit after 12 months. EDSS worsening will be defined as a ⩾1.0-point increase from a baseline score of ⩽5.5 or a ⩾0.5-point increase from a baseline score of ⩾6.0. T25FW and 9HPT worsening will be defined as ⩾20% worsening from baseline.

    Time frame: 48 months to 108 months

Secondary outcomes

  1. Brain volume loss, month 6 to month 36

    To determine whether an EHT approach to DMT, defined as use of one of four monoclonal antibodies (alemtuzumab, natalizumab, rituximab, or ocrelizumab) as first-line therapy, is more effective than an escalation of treatment approach in reducing normalized whole brain volume loss measured using MRI in PwRRMS from Month 6 to Month 36.

    Time frame: Month 6 to month 36

  2. Proportion of participants with progression

    Proportion of participants with a multidimensional composite comprised of EDSS progression (\>1.5 points for those with EDSS of 0 at Baseline, ≥1.0 for those with EDSS of 0.5-5.0 at Baseline, and \>0.5 points for those with EDSS above 5.0 at Baseline), 20% change in MSFC-4 subcomponents (T25FW, 9HPT), 10% in SDMT or, 1 line change in LCLA confirmed over 12 months.

    Time frame: Baseline to 36 months

  3. Change in MSIS-29, baseline to 36 months

    Change in MSIS-29 responses from participants

    Time frame: Baseline to 36 months

  4. Change in Neuro-QOL, baseline to 36 months

    11 subscales, each is scored separately, there is no composite score Physical Domains: Upper Extremity Function (Fine Motor, ADL): Higher scores indicate: Better Functioning Lower Extremity Function (Mobility): Higher scores indicate: Better Functioning Fatigue: Higher scores indicate: Worse Functioning Sleep Disturbance: Higher scores indicate: Worse Functioning Mental Domains: Cognition Function: Higher scores indicate: Better Functioning Stigma: Higher scores indicate: Worse Functioning Anxiety: Higher scores indicate: Worse Functioning Depression: Higher scores indicate: Worse Functioning Positive Affect and Well -being: Higher scores indicate: Better Functioning Social Domains: Ability to Participate in Social Roles and Activities: Higher scores indicate: Better Functioning Satisfaction with Social Roles and Activities: Higher scores indicate: Better Functioning

    Time frame: Baseline to 36 months

  5. Time to reach SPMS, month 48 to month 108

    To determine the efficacy of an EHT approach as compared to an escalation approach as reflected by the following: * Time to reach secondary progressive MS (SPMS) as defined by worsening on the EDSS (3 strata definition for EDSS worsening plus EDSS score of ≥4 and pyramidal score ≥2), confirmed at 12 months, over 108 months * Proportion of participants with a 20% or greater change in T25FW at 108 months. * Proportion of participants with a 20% or greater change in 9HPT at 108 months. * Proportion of participants with a 20% or greater change in the SDMT at 108 months.

    Time frame: 48 months to 108 months

  6. Efficacy difference between EHT and ESC, month 48 to month 108

    To determine the efficacy of an EHT approach as compared to an escalation approach as reflected in the following patient-reported outcomes: * The change in participant-perceived symptoms as measured by the MSIS-29. * The change in participant quality of life as measured by Neuro-QOL.

    Time frame: 48 months to 108 months

  7. Safety difference between EHT and ESC, month 48 to month 108

    To determine the safety of an EHT approach as compared to an escalation approach as reflected in the following: * Proportion of participants with SAEs * Rate of SAEs * Proportion of participants with DMT discontinuation due to safety or tolerability concerns * Cumulative on-therapy TSQM Response scores

    Time frame: 48 months to 108 months

07

Study locations

30 sites
08

References and documents

Publications

  • Tallantyre EC, Planchon SM, Howard H, Mays J, Frowd N, Cohen JA, Coles A, Hersh CM, Miller DM, Dever M, Gray EH, LaRocca NG, Nakamura K, Bale C, Covey-Crump G, Alvarez E, Arun T, Brownlee WJ, Craner M, Freeman L, Frost N, Goldman MD, Gupta RK, Harding KE, Hobart J, Hutton GJ, Hyland MH, Kalra S, Kannan M, Kantarci O, Lashley D, Lily O, Mahad D, Nicholas JA, Nicholas R, Paling D, Pearson OR, Rice CM, Samudralwar R, Schmalstieg WF, Singh M, Zune The E, Weinstock-Guttman B, Zabeti A, Love TE, Gunzler DD, Liu Y, Gerry S, Evangelou N, Ontaneda D. Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS). Mult Scler. 2026 Jun;32(7):722-736. doi: 10.1177/13524585261449988. Epub 2026 May 31. PubMed 42218617 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2019 (actual). Primary completion is estimated for Jul 2027, 102 months after the start.

Of 28 phase 4 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 66. This study's planned 102 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2018
First posted
May 24, 2018
StartActual
Jan 3, 2019
Primary completionEst.
Jul 30, 2027
CompletionEst.
Jul 30, 2027
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03535298
Responsible party
Daniel Ontaneda, MD (Principal Investigator, The Cleveland Clinic) — Principal investigator
First posted
May 24, 2018
Start date
Jan 3, 2019
Primary completion
Jul 30, 2027 (estimated)
Completion
Jul 30, 2027 (estimated)
Last update
Aug 31, 2026

Study contacts

Daniel Ontaneda, MD, MSc
principal investigator · The Cleveland Clinic
Nikos Evangelou, MD, DPhil
principal investigator · University of Nottingham

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Natalizumab · Glatiramer

Start the discussion